1909.6000 -29.70 (-1.53%)
NSE Oct 13, 2025 15:31 PM
Volume: 872.8K
 

1909.60
-1.53%
IDBI Capital
Glenmarks's Q1FY19 results were a mixed bag, while the sales and EBITDA were 9.9%/ 10.9% below our expectations; APAT was up 7.8% over IDBIEst. given higher Other Income which included Rs125Cr of forex gain. Sales were down 8.4% YoY (-5% QoQ) at...
Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2013.9
More from Glenmark Pharmaceuticals Ltd.
Recommended